These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Maier SK; Hammond JM Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850 [TBL] [Abstract][Full Text] [Related]
3. Lenalidomide. Weisel K; Kanz L Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803 [TBL] [Abstract][Full Text] [Related]
4. Lenalidomide for treatment of myelodysplastic syndromes. Komrokji RS; List AF Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699 [TBL] [Abstract][Full Text] [Related]
5. Properties of thalidomide and its analogues: implications for anticancer therapy. Teo SK AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Shortt J; Hsu AK; Johnstone RW Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436 [TBL] [Abstract][Full Text] [Related]
12. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Leitch HA; Buckstein R; Shamy A; Storring JM Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762 [TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory therapy for myelodysplastic syndromes. Sokol L; List AF Int J Hematol; 2007 Nov; 86(4):301-5. PubMed ID: 18055335 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347 [TBL] [Abstract][Full Text] [Related]
15. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Vallet S; Witzens-Harig M; Jaeger D; Podar K Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide, a thalidomide derivative, shows promise in various applications. Oestreicher P ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579 [No Abstract] [Full Text] [Related]
17. Lenalidomide: the emerging role of a novel targeted agent in malignancies. Kalmadi S; Baz R; Mahindra A Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946 [TBL] [Abstract][Full Text] [Related]
18. The thalidomide saga. Melchert M; List A Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076 [TBL] [Abstract][Full Text] [Related]
19. [IMiDs in hematology]. Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980 [TBL] [Abstract][Full Text] [Related]
20. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Palumbo A; Freeman J; Weiss L; Fenaux P Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]